All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

EMA Grants PRIME Designation to BGB-16673 for Previously Treated Waldenström Macroglobulinemia

August 4th 2025

The BTK degrader BGB-16673 has received PRIME designation from the EMA for the treatment of patients with Waldenström macroglobulinemia.

ALPHA3 Trial of Cema-Cel in LBCL Proceeds With Fludarabine/Cyclophosphamide Lymphodepletion Regimen

August 4th 2025

Fludarabine plus cyclophosphamide lymphodepletion will be used in the phase 2 ALPHA3 trial of first-line consolidation cema-cel in patients with LBCL.

Retrospective Data Show Feasibility of Checkpoint Inhibition in Patients With Cancer and Neurologic Autoimmune Disorders

August 4th 2025

A retrospective study showed immune checkpoint inhibitors may be an option in appropriate indications for patients with neurologic autoimmune disorders.

Casdatifan Plus Cabozantinib Shows Early-Phase Efficacy in Clear Cell RCC

August 4th 2025

Rana R. McKay, MD, FASCO, discusses findings from the ARC-20 trial of casdatifan plus cabozantinib in pretreated clear cell renal cell carcinoma.

Consensus Guidelines Needed to Further Optimize PARP Inhibition, Molecular Imaging, and ARPI Use in Prostate Cancer Management

August 4th 2025

Rana R. McKay, MD, expands on key updates and knowledge gaps in prostate cancer management discussed at the Bridging the Gaps in Prostate Cancer meeting.

Five Under 5: Top Oncology Videos for the Week of 7/27

August 3rd 2025

The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.

First‑in‑Class mRNA‑2416 Shows Tolerability, Biologic Activity in Ovarian Cancer and Other Advanced Solid Tumors

August 3rd 2025

mRNA‑2416, alone or with durvalumab, was well tolerated and biologically active in advanced solid tumors and ovarian cancer.

The OncFive: Top Oncology Articles for the Week of 7/27

August 2nd 2025

Perioperative durvalumab sBLA gets priority review in gastric/GEJ cancer, acalabrutinib combination sNDA under review in CLL, and more.

EMA Grants Orphan Drug Designation to Nuvisertib for Myelofibrosis

August 2nd 2025

Nuvisertib has received orphan drug designation from the EMA for patients with myelofibrosis.

TAR‑200 Could Alter Nonsurgical Management of BCG‑Unresponsive NMIBC

August 1st 2025

Joseph Jacob, MD, MCR, discusses how TAR‑200 could represent a new treatment avenue in BCG‑unresponsive, high-risk NMIBC.

Final Phase 3 Data Underscore Role of Pembrolizumab/Chemoradiotherapy in High Risk, Locally Advanced Cervical Cancer

August 1st 2025

Linda Duska, MD, MPH, discusses final results of KEYNOTE A18 for pembrolizumab plus chemoradiotherapy in high risk, locally advanced cervical cancer.

Oral SERDs and PI3K Inhibitors Move the Needle Beyond CDK4/6 Inhibitors in Metastatic Breast Cancer

August 1st 2025

Katherine C. Ansley, MD, discusses the role of oral SERDs and PI3K and AKT inhibitors for the treatment of metastatic breast cancer.

Mayo Clinic Treats First Person in the US With a Novel Radiopharmaceutical Therapy for Breast Cancer

August 1st 2025

Researchers are leading the nation in using powerful and precise radioactive drugs to treat people with complex cancers.

Brazilian Approval Is Sought for Tafasitamab Plus Rituxumab/Lenalidomide in R/R Follicular Lymphoma

August 1st 2025

A supplemental application has been submitted to Brazil’s health regulatory agency, seeking the approval of tafasitamab for follicular lymphoma.

VT3989 Receives FDA Orphan Drug Designation for Mesothelioma

August 1st 2025

The first-in-class TEAD autopalmitoylation inhibitor VT3989 has received FDA orphan drug designation for the treatment of patients with mesothelioma.

OncLive’s July Roundup of Key FDA Approvals in Oncology: 4 Decisions to Know

August 1st 2025

Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.

Minimally Invasive Surgery and Multidisciplinary Collaboration Improve Recovery Time in Lung Cancer

August 1st 2025

Geoffrey B. Pelz, MD, discusses the evolution of thoracic surgical oncology, along with newer minimally invasive approaches to surgery in lung cancer.

FDA Issues CRL for Odronextamab in Relapsed/Refractory Follicular Lymphoma

August 1st 2025

The FDA has issued a complete response letter for odronextamab in relapsed or refractory follicular lymphoma.

China’s NMPA Accepts sNDA for Ivonescimab Plus Chemotherapy in Frontline Advanced Squamous NSCLC

July 31st 2025

Ivonescimab plus chemotherapy is under review in China for the frontline treatment of patients with advanced squamous non–small cell lung cancer.

Close Collaboration Between Oncology and Neurology Vital in Managing Patients With NAIDs Receiving ICIs for Cancer

July 31st 2025

Shailee S. Shah, MD, discusses the frequency and severity of neurologic autoimmune disorder exacerbation in patients with cancer receiving ICIs.